CETP inhibitor News and Research

RSS
A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP).
Clinical benefit of LDL cholesterol lowering therapies could depend on reduction in apoB particles

Clinical benefit of LDL cholesterol lowering therapies could depend on reduction in apoB particles

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers report results from Phase III DEFINE study for coronary heart disease

Determining success or failure in cholesterol-controlling drugs

Determining success or failure in cholesterol-controlling drugs

Issues on cholesterol: diet, statins and genetics

Issues on cholesterol: diet, statins and genetics

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression